A2a adenosine receptor antagonists

A method for treating a disease or condition in a mammal that can be treated with an A2A adenosine receptor antagonist compound comprising administering to a mammal in need thereof a therapeutically effective dose of a compound having the structure of Formula I:

• wherein
• R1 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C2-10 alkenyl, or optionally substituted C2-6 alkynyl;
• R2 is hydrogen, optionally substituted C1-4 alkyl, —X—O—P(O)(OR)2, or —X—O—R7, in which X is C1-4 alkylene, R is hydrogen or C1-6 alkyl, and R7 is C1-6 alkyl;
• R3 is hydrogen, optionally substituted C1-4 alkyl, or a 5 or 6 membered optionally substituted monocyclic heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, sulfur and nitrogen;
• R4 and R5 are independently methyl or hydrogen;
• and
• R6 is optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted cycloalkyl,
• or a pharmaceutically acceptable salt, ester, prodrug, or hydrate thereof.